Share Name Share Symbol Market Type Share ISIN Share Description
Skinbiotherap. LSE:SBTX London Ordinary Share GB00BF33H870 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 14.75p 4,000 08:00:00
Bid Price Offer Price High Price Low Price Open Price
14.50p 15.00p 14.75p 14.75p 14.75p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -0.7 -1.1 - 17.51

Skinbiotherap. (SBTX) Latest News

More Skinbiotherap. News
Skinbiotherap. Takeover Rumours

Skinbiotherap. (SBTX) Share Charts

1 Year Skinbiotherap. Chart

1 Year Skinbiotherap. Chart

1 Month Skinbiotherap. Chart

1 Month Skinbiotherap. Chart

Intraday Skinbiotherap. Chart

Intraday Skinbiotherap. Chart

Skinbiotherap. (SBTX) Discussions and Chat

Skinbiotherap. (SBTX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
07:27:0015.004,000599.80O
2018-06-21 15:25:2814.505,000725.00O
2018-06-21 15:24:3114.6075,00010,950.00O
2018-06-21 14:48:2814.5049371.49O
2018-06-21 13:13:5115.001,000150.00O
View all Skinbiotherap. trades in real-time

Skinbiotherap. (SBTX) Top Chat Posts

DateSubject
22/6/2018
09:20
Skinbiotherap. Daily Update: Skinbiotherap. is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SBTX. The last closing price for Skinbiotherap. was 14.75p.
Skinbiotherap. has a 4 week average price of 14.50p and a 12 week average price of 8.25p.
The 1 year high share price is 18.90p while the 1 year low share price is currently 7.35p.
There are currently 118,708,494 shares in issue and the average daily traded volume is 218,637 shares. The market capitalisation of Skinbiotherap. is £17,509,502.87.
29/5/2018
09:23
bobalot: SkinBioTherapeutics shares in UK government grant with Manchester University 29 May 2018 | 09:12am StockMarketWire.com - SkinBioTherapeutics said it had been selected as an industrial partner in a grant awarded by the the UK government's Biotechnology and Biological Sciences Research Council to the University of Manchester. The grant of around £600k provided the university with funding for up to three years to investigate how ageing affects the skin and in particular, its microbiome. At 9:12am: [LON:SBTX] SkinBioTherapeutics Plc share price was 0p at 17p Story provided by StockMarketWire.com, htTp://www.stockmarketwire.com/article/5988334/SkinBioTherapeutics-shares-in-UK-government-grant-with-Manchester-University.html
21/4/2018
21:46
onedayrodders: I posted this on OPTI board but will be of interest here .. Hey all, myself and Trotters were at the UK Investor show today and were chatting with SOH for quite a while.. I'm sure Trotters will be posting a few nuggets later but I know the SBTX divi is an Important issue many have asked about so here is what he said. They are absolutely aware and focused on making this as fair as possible by not allowing short term traders to benefit or damage either OPTI or SBTX share price. Options being discussed ... 1. Lock in period - Unlikely as regulators do not like this type of arrangement and view it as restricting the market. 2. Staggered benefit, for example, OPTI will give shareholders say 1000 SBTX shares and promise another 1000 shares the next year providing the first 1000 shares have not been sold. 3. Take advantage of increasing interest in Skinbiotix by selling a % of OPTI's stake in SBTX to by Institutional investors and delivering a SBTX cash divi. (Therefore delivering the SBTX divi promise, adding long term Institutional shareholders and removing volatility in the share price - my take) The qualifying for any divi, either shares or cash will be controlled by a record date and that cannot be a date in the past and will be from close of business on the day the divi details are announced. So they will be looking to time that towards the end of the day to allow the smallest window possible for the AIM trading vultures (my words not his !) That's from memory so hope I got it right (Trotters..correct me if I'm wrong) ODR
21/4/2018
08:30
parob: What MC do peeps think we will be looking at should the human trials be successful in Sept?I'm thinking £50 million which would equate to a share price of 42p.
03/4/2018
08:07
elrico: Broker, Hybridan suggested SkinBiotix® could be worth £98.1m, but thought to be the riskiest of the four divisions at the time, though, a risk ratio of 95% seems extreme. At the UK Investor show in April 2016, Stephen O'Hara divulged the future potential valuation of SkinBiotix® as a demerged company could be worth £250m, this was not his valuation, but that of an independent industry source. However, before we get carried away with the valuation, there must be the usual caveats associated with the “need for the company to successfully fully exploit all the opportunities offered by the IP to reflect the early nature of the opportunity and the challenges of taking products to regulated markets.” Another point Stephen O'Hara makes in relation to the SkinBiotix investment, “there was no recognition of its value by shareholders in the share price (in fact from memory it dropped - 20th October).” Yet it's IPO last April unlocked £9m+ of value and handing it the keys to the vault, enabling the company to progress at it's own pace with its own funds independent of its parent company. With £3.6m at the bank, the BOD believe this is enough to see it through to commercial reality. Today's announcement should be an indication that a major consumer goods company has shown its intent and has no intention of allowing another company steal a march on it. I think this company is Johnson & Johnson; Since early 2014 UoM has already done extensive research with Johnson & Johnson, explore the emerging science around the human microbiome and its impact across several areas of health and disease, including potential applications of probiotic extracts for prevention and treatment of skin, oral, and respiratory conditions. Dr Catherine O’Neill and Dr Andrew McBain, lead on the research project with Johnson & Johnson Innovation.Since early 2014 UoM has already done extensive research with Johnson & Johnson, explore the emerging science around the human microbiome and its impact across several areas of health and disease, including potential applications of probiotic extracts for prevention and treatment of skin, oral, and respiratory conditions. Dr Catherine O’Neill and Dr Andrew McBain, lead on the research project with Johnson & Johnson Innovation.
03/4/2018
07:27
opodio: Another worthless announcement to prop the share price as it heads to 0p
27/3/2018
08:45
rafboy: I don’t think people realise how cheap this is. Once the human skin trials are complete it is very likely to be followed in short order by a commercial deal. This should all happen by year end. You will be paying 3 or 4 times the current share price then IMHO.
15/2/2018
15:19
incanus: It is normal for a company share price to rise in anticipation of a divi just as it is normal for the share price to depreciate by about the same amount ex divi. SBTX may decline more significantly if there is no locked shares. Naivety is astonishing. Let us hope management in both companies have some substance to shore up both shares.
11/12/2017
10:45
loungeact: Never seen anyone is such emotional turmoil over a share price. Your actions are so desperate it's hilarious. Your need to ramp and flood the page with repeated information because the share price is down a little. Such a fool. DESPERATE, DESPERATE STUFF!!
23/11/2017
13:33
elrico: Peeps - can we leave my name out of this debate now, please. It is patently obvious Bobalot is very green, nieve and now we can now see he cannot to be trusted to be honest in debate. He remains filtered because he adds nothing other than volume of useless traffic to this thread. I gather I'm some sort of deceiver, a con artist and have my facts wrong. Be very careful Bob, one poster that used the "ripelrico" pseudonym has had his ADVFN account closed as well as his own, after he posted falsehoods about me. And yes, he had to pay my legal fee 1x letter to ADVFN. For the record: SBTX is no longer a subsidiary of OPTI, SBTX is a separate legal entity of its own as a PLC. I never suggested SBTX is a subsidiary, had I done so I would have been wrong and would, once corrected would have been man enough to stand corrected, as I have been previously. Ref controlling interest: OPTI could use its 41.9% shareholding to influence at a AGM. They don't currently have a controlling interest, but a majority holding, significant enough to influence over say anything Seneca wanted to the direction of SBTX should it have a need - (purely as an example). SOH does not hold any SBTX shares that I am aware of, but you point (PG) is a valid one.
23/11/2017
12:00
bobalot: Go look up Elrico's posts for the past week...he has made false statements quite often about SBTX saying it is a subsidiary. OPTI do not have a controlling interest....that would require a 50%+ holding and OPTI only have 41% some of which they plan to give away according to an SOH interview. What you have said above is misguided and technically wrong....in denial about reality imo. Selling off a valuable asset such as a division depletes inherent value in OPTI -- they have done a debt for equity swap by converting their original investment into debt and then swapping the debt for shares. OPTI will not benefit from an income stream from SBTX but they may benefit from an appreciating share price if that happens. OPTI have no legal leverage over SBTX and SOH is simply a NED/ director advisor. TAKE A LOOK AT THE FOLLOWING POSTS: elrico 21 Nov '17 - 10:31 - 876 of 933    4   0 elrico 21 Nov '17 - 11:09 - 878 of 933    5   0 elrico 22 Nov '17 - 10:24 - 887 of 933    3   0
Skinbiotherap. share price data is direct from the London Stock Exchange
add chat code
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20180622 09:39:30